Plain-English translation of NCT07655115 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help children and teenagers with autism spectrum disorder. The trial will first compare the medication to a placebo (a dummy pill with no active ingredient) in a short test, then offer 10 weeks of the actual medication to see how it affects symptoms and quality of life.
Many young people with autism struggle with social interaction, anxiety, and repetitive behaviors that affect their daily lives. Researchers believe this medication might help address these challenges by affecting how the brain processes certain chemicals.
You likely qualify if…
You likely don't qualify if…
You will first participate in a short crossover phase where you'll take either the medication or a placebo for a brief period, with a washout period in between, to see how your brain responds. Then, if you continue, you'll enter a 10-week open-label phase where you'll take the actual medication—starting with a 4-week period where the dose is gradually increased, followed by 6 weeks at a stable dose. Throughout the study, you'll have brain activity measurements (EEG and eye tests) and complete questionnaires about your social skills, anxiety, behavior, and overall quality of life.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
France
Spain